Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route (Ascending) Package Effective Date Package Discontinuation Date Status
00310-0512-28 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral April 1, 2018 July 31, 2021 In Use
00310-0512-60 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Oct. 31, 2017 In Use
00310-0512-95 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral April 1, 2020 July 31, 2025 In Use
50242-0210-12 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sept. 28, 2022 In Use
50242-0210-60 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral July 1, 2021 In Use
50242-0210-83 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral July 1, 2021 In Use
50242-0210-86 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral Sept. 15, 2020 Feb. 11, 2022 In Use
50242-0210-90 50242-0210 Pralsetinib Gavreto 100.0 mg/1 Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Oral July 1, 2021 In Use
42388-0011-14 42388-0011 Cabozantinib COMETRIQ Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 29, 2012 In Use
42388-0012-14 42388-0012 Cabozantinib COMETRIQ Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 29, 2012 In Use
51991-0890-33 51991-0890 Erlotinib Hydrochloride Erlotinib 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 April 30, 2024 In Use
51991-0891-33 51991-0891 Erlotinib Hydrochloride Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 July 31, 2025 In Use
51991-0892-33 51991-0892 Erlotinib Hydrochloride Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 July 31, 2025 In Use
54838-0555-50 54838-0555 Ondansetron Hydrochloride Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 27, 2011 Nov. 30, 2024 In Use
00069-1031-30 00069-1031 Talazoparib Talzenna 0.1 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
00069-1235-30 00069-1235 Talazoparib Talzenna 0.35 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 21, 2023 In Use
00121-0885-08 00121-0885 Prednisolone Prednisolone 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 12, 2023 In Use
00121-0885-16 00121-0885 Prednisolone Prednisolone 15.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Sept. 12, 2023 In Use
00173-0909-13 00173-0909 Niraparib ZEJULA 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0912-13 00173-0912 Niraparib ZEJULA 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0912-61 00173-0912 Niraparib ZEJULA 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0915-13 00173-0915 Niraparib ZEJULA 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00173-0915-61 00173-0915 Niraparib ZEJULA 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral June 27, 2023 In Use
00480-4053-56 00480-4053 Gefitinib Gefitinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral June 21, 2023 In Use
00591-4365-60 00591-4365 Abiraterone acetate Abiraterone acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral July 13, 2023 In Use

Found 10,000 results in 9 milliseconds — Export these results